Latest and Past News
-
Health Canada approves Altuviiio
MONTRÉAL, March 31, 2025 – Health Canada has granted marketing approval to Altuviiio (efanesoctocog alfa) for the treatment of hemophilia A in children, adolescents and...
-
Hemgenix 4-year results show steady durability
MONTREAL, March 12, 2025 – Results from the HOPE-B trial for the hemophilia B gene therapy, Hemgenix, show steady expression of factor IX (FIX) four...
-
Development halts in first-generation gene therapies
MONTREAL, February 25, 2025 – On February 20, Pfizer announced that it was stopping development of its hemophilia B gene therapy, Beqvez. It cited “soft...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2025 ISSUE ONE of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Now accepting applications for the James Kreppner Scholarship and Bursary Program
The competition for the James Kreppner Memorial Scholarship and Bursary Program is now open. DEADLINE TO APPLY: APRIL 30, 2025 CLICK HERE for all the details.
-
Your FEEDBACK matters to us!
The CHS is currently developing the next CHS Strategic Plan. We would appreciate your insights into how we can further our mission and enhance our...
-
Best wishes from the CHS!
Please CLICK HERE to read a special message from CHS President, Emil Wijnker, and Chief Executive Officer, Sarah Ford.
-
CHS survey of people with hemophilia A and their caregivers
In June and July 2024, the Canadian Hemophilia Society conducted an online survey regarding the lived experience of people with hemophilia A and their caregivers....
-
Rendez-vous 2025
The Canadian Hemophilia Society is delighted to invite you to attend Rendez-vous 2025 coming up May 1-4, 2025, in Winnipeg. CLICK HERE for a glimpse at the...
-
Biomarin limits marketing of its FVIII gene therapy, Roctavian
SAN RAFAEL, California, August 5, 2024 — Biomarin has announced that it will limit commercial, research and manufacturing programs for its factor VIII gene therapy...
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the 2024 ISSUE TWO of the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia...
-
Contributing to the advancement of scientific knowledge
PREAMBLE We have already come to the end of this important series of articles about the national board and operational committees on which our volunteers...
-
The value in sharing our strengths
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the International...
-
Playing a key role in shaping the future of people living with bleeding disorders
PREAMBLE In our special series of articles on the numerous committees our volunteers sit on, it is our pleasure to now present you the latest...